Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort - PubMed
2 hours ago
- #drug repurposing
- #cancer therapy
- #observational study
- Study evaluated real-world outcomes of ivermectin and mebendazole in 197 cancer patients via a U.S. telemedicine platform.
- High adherence: 86.9% completed initial prescription, 66.4% remained on therapy at six months.
- Clinical Benefit Ratio was 84.4%, with 48.4% reporting tumor regression or no evidence of disease, and 36.1% stable disease.
- Side effects were mild and dose-dependent, primarily gastrointestinal, reported by 25.4%; 93.6% continued therapy after adjustment.
- Findings support the need for randomized controlled trials to further investigate this combination therapy.